Most of the private equity ophthalmology platforms that exist today were assembled between 2018 and 2019. A standard buyout fund runs about ten years, which means those platforms face a forced sale around 2028 and 2029 whether the market is ready or not. The cataract demand curve does not care about fund life. It keeps climbing well into the 2040s as the last of the baby boomers age into the disease. A platform built on a ten-year clock is structurally required to sell the asset right as the asset enters its best decade. That mismatch between when capital must exit and when demand peaks is the whole opportunity, and it is not a matter of opinion. It is written into the fund documents on one side and the census tables on the other.

Why Ophthalmology Exits Are Frozen Right Now

The forced-sale problem stopped being theoretical sometime in the last two years. More than sixteen thousand companies globally have now been held by buyout funds for more than four years, which is about 52 percent of all buyout-backed inventory and the highest share on record, according to McKinsey's 2026 global private markets report. Funds are sitting on assets they cannot sell at the price they need, and the longer they hold, the closer they drift to the end of the fund life that forces a sale regardless of price.

Exits across private equity have slowed to the point that global distribution yield in 2024 fell to roughly 11 percent, the lowest in more than a century by Bain's measure. In physician services specifically, more than half of dermatology, ophthalmology, and gastroenterology practices acquired by private equity were resold within three years, and nearly all of those resales went to another private equity buyer rather than to a strategic acquirer, according to research published in Health Affairs Scholar. The model was always to buy a practice, bolt it onto a platform, and sell the platform to a larger fund at a higher multiple. That treadmill depended on each fund finding a bigger fund willing to pay more. When the music slowed, the platforms that had not yet sold found themselves stranded, holding assets with a clock running and no obvious buyer at the multiple the model assumed.

How the Ophthalmology Demand Curve Actually Moves

While the exit window narrows, demand does the opposite. United States cataract volume is projected to climb from roughly four million procedures a year toward six million by 2030, and the aging curve does not flatten at the end of the decade. Ophthalmology is also the most independent specialty in American medicine, with about 70.4 percent of ophthalmologists still in private practice according to the American Medical Association's 2024 benchmark survey, which means the supply of acquirable practices remains large and fragmented even after a decade of consolidation attempts. Retirements already outpace new graduates by well over a hundred ophthalmologists a year, so the number of surgeons available to meet the rising demand is shrinking while the demand itself accelerates.

A surgical specialty with rising demand, falling supply of surgeons, and a fragmented base of retiring owners with no obvious successor is a fifteen-year tailwind, not a ten-year trade. The fund structure was never designed to capture a tailwind that long. It was designed to buy, improve, and flip inside a decade, which works when multiples are expanding and buyers are plentiful, and breaks precisely when neither is true.

What a Buyer Who Never Sells Does Differently in Ophthalmology

A permanent holder reads the 2028 forced-sale wall as a buying calendar. The platforms that have to sell will be selling into a market where strategic buyers are scarce and the only ready capital is the next fund down the line, which is the same crowded exit door that produced the 11 percent distribution yield. A buyer with no fund clock can acquire the practices and surgical assets that the demographic curve is about to reward, hold them through the peak, and never face the denominator problem that defines the rest of the industry.

The advantage compounds in a way that is easy to underestimate. Every year the permanent holder does not have to sell is a year of facility fees, surgical volume, and premium lens revenue accruing to the owner rather than being packaged for the next buyer. The ten-year clock is the competitor's constraint. The thirty-year wave is the permanent holder's asset. The two were never going to line up, and the widening gap between them is where patient capital gets paid for the discipline of simply not selling.

There is a second-order effect worth naming. As the forced sellers move their inventory in 2028 and 2029, they will be competing for the same scarce pool of buyers at the same moment, which pushes exit multiples down precisely when the most assets need to clear. A buyer with no clock sits on the other side of that dynamic, able to acquire from motivated sellers at prices set by their urgency rather than by the asset's underlying worth. The demographic wave makes the assets more valuable over time, and the exit freeze makes them cheaper to acquire in the near term. A permanent holder is the rare participant positioned to benefit from both halves of that trade at once, buying into a forced-seller market and holding into a rising-demand one.

What History Says About the Ophthalmology Exit Squeeze

The pattern is not speculative, because the physician-services sector has already shown how it ends. Research published in Health Affairs Scholar found that more than half of dermatology, ophthalmology, and gastroenterology practices acquired by private equity were resold within three years, and that nearly all of those resales went to another private equity buyer rather than to a strategic acquirer. The entire model depended on a larger fund standing ready to pay a higher multiple, which works only while capital is plentiful and exits are easy. When the broader market froze, that chain of buyers thinned out, and the platforms still holding practices found themselves without the exit the model assumed.

A reasonable counterpoint is that strategic acquirers, the large publicly traded healthcare companies, can absorb some of this inventory, and a few high-profile deals show they sometimes will. The limitation is scale and timing. Strategic buyers are selective, they pay for quality rather than for a fund's need to exit, and they cannot absorb the volume of platforms that a wave of 2018-vintage funds will need to clear at roughly the same time. The arithmetic of a crowded exit does not improve because a handful of strategic deals close. It improves only for the seller lucky enough to be one of the few, and gets worse for everyone else competing for the same narrow door.

For a permanent holder, none of this is a threat, because the model never depended on an exit in the first place. The fifteen-year demand tailwind rewards the owner who holds, the near-term exit freeze rewards the buyer who has cash and no clock, and the two forces point the same direction for the only participant built to act on both. The competitor's structural constraint is the permanent holder's structural advantage, and the gap between them widens every quarter the exit market stays frozen.

This article is for general educational purposes and is not legal or financial advice.

Verdira is a healthcare acquisition platform focused on ophthalmology practices. Physician ownership. Transparent structure. No volume quotas. If you're a practice owner thinking about succession or a physician exploring ownership, we're open to thoughtful conversations.

Contact info@verdira.com | 307-381-3734 | verdira.com